# EyeBiotech Ltd.: Phase 3 study closed enrollment, 1054 enrolled (Diabetic Macular Edema (DME))

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | EyeBiotech Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME |
| NCT ID | NCT06957080 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Diabetic Macular Edema (DME) |
| Intervention types | drug |
| Target enrollment | 1054 |
| Site countries | United States, Argentina, Brazil, Colombia, Japan, Puerto Rico |
| Posted | 2025-05-04 |
| Planned start | 2025-04-16 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 1054 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06957080). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.